Financial Performance - The company achieved operating revenue of ¥780,260,212.25, representing a 99.96% increase compared to the previous year[4] - Net profit attributable to shareholders reached ¥299,804,792.40, a growth of 174.61% year-over-year[4] - Basic earnings per share increased to ¥4.64, reflecting a 165.14% rise from the previous year[4] - The increase in net profit was driven by steady sales growth and improved gross margins[8] Assets and Equity - Total assets at the end of the reporting period amounted to ¥1,432,179,772.46, up 75.62% from the beginning of the period[5] - Shareholders' equity attributable to the company increased by 116.64% to ¥953,681,856.16[5] - The company's weighted average return on equity (ROE) before deductions was 43.96%[6] Research and Development - The company has intensified R&D investments and actively developed new products, contributing to sustainable revenue growth[6] Market Activity - The company completed its listing on the Beijing Stock Exchange, which enhanced its capital base and liquidity[8] Cautionary Note - The company warns that the financial data presented are preliminary and subject to change upon final audit[9]
锦波生物(832982) - 2023 Q4 - 年度业绩